Version July 2025
| Regimen for treatment of rifampin-resistant, fluoroquinolone-resistant TB: BPaL regimen* | |
| Bedaquiline | 400 mg once daily for two weeks, then 200 mg three times weekly for subsequent 24 weeks |
| Pretomanid | 200 mg once daily for 26 weeks |
| Linezolid | 600 mg once daily for 26 weeks |
| Regimen for treatment of rifampin-resistant, fluoroquinolone-susceptible TB: BPaLM regimen¶ | |
| Bedaquiline | 400 mg once daily for two weeks, then 200 mg three times weekly for subsequent 24 weeks |
| Pretomanid | 200 mg once daily for 26 weeks |
| Linezolid | 600 mg once daily for 26 weeks |
| Moxifloxacin | 400 mg once daily for 26 weeks |
BPaL: bedaquiline, pretomanid, and linezolid; BPaLM: bedaquiline, pretomanid, linezolid, and moxifloxacin.
* Medications should be administered seven days per week orally with food, with directly observed therapy for five of seven days per week.
¶ Medications should be administered seven days per week orally with food (avoiding milk, antacids, or other cationic items), with directly observed therapy for five of seven days per week.
